News

The trial known as MONALEESA-7 met its primary endpoint of progression-free survival (PFS), stated Novartis. Through the late-stage trial, the CDK4/6 inhibitor Kisqali in combination with oral hormonal

The NEPLEX (nephron on a chip with cellular and extracellular matrix complexity) consortium will aggregate crucial technologies to develop and build a novel drug discovery device called Nephron-on-a-Chip.

Spark Therapeutics will enroll up to five additional participants in the current Phase 1/2 clinical trial who will receive SPK-9001 manufactured using an enhanced process to test its

Zelboraf has been approved for the first line treatment of patients with Erdheim-Chester disease (ECD) and who are positive for BRAF V600 mutation. ECD is a rare and serious

With Splunk, Recursion has combined biological science with machine learning to generate and analyze data from tens of thousands of images of cell cultures and trillions of DNA

The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active rheumatoid arthritis (RA),

Cellectis agreed with the FDA to the following main revisions to be implemented in Phase 1 UCART123 protocols to lift the hold: Decrease of the cohort dose level

The company has submitted marketing authorization application (MAA) to the EMA for Kymriah to treat children and young adults with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia

The buyer will pay Valeant a 6% royalty on worldwide sales of libido drug Addyi (flibanserin), beginning 18 months from the signing of the sale agreement. In August 2015, Valeant